Pharmacogenetic Study of Pioglitazone and Quetiapine XR Treatment Response in Mood Disorders
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 42
- 试验地点
- 1
- 主要终点
- Genetic markers associated with treatment response
研究概览
简要总结
Obtain phenotypic data and a DNA/blood sample from mood disorder patients undergoing pioglitazone or quetiapine XR treatment as a part of an IRB approved clinical trial conducted at the Mood Disorders Program. Pioglitazone treatment is examined in metabolic syndrome comorbid with bipolar depression (IRB # 07-08-24) and unipolar depression (IRB # 07-07-20). Quetiapine XR treatment is examined in generalized anxiety disorder comorbid with bipolar depression (IRB # 10-06-19) and unipolar depression (IRB # 12-01-29). Please refer to the respective IRB protocols for more information.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Must have participated in IRB protocols 10-06-19, 12-07-29, 07-07-20, and 07-08-24
- •Patient must give consent to participate, sign and date the IRB approved written informed consent form prior to the initiation of any procedures for this study
- •Patient must be diagnosed with Bipolar Disorder or Major Depressive Disorder
- •Patient must be at least 18 years old
- •Patient must be willing to give a blood sample
排除标准
- •Patient lacks the capacity to provide informed consent
结局指标
主要结局
Genetic markers associated with treatment response
时间窗: Up to 1.5 years
Genetic markers in PPARG, 5-HT2A, CYP3A4 and CYP2C8 genes known to be related in the pharmacodynamics and pharmacokinetics of pioglitazone or quetiapine XR will be associated with treatment response.
次要结局
未报告次要终点